title: Serum alpha 2-HS glycoprotein concentration in patients with hematological malignancies. A follow-up study.
abstract: We observed significantly reduced serum alpha 2-HS glycoprotein concentrations in patients with acute lymphocytic, acute nonlymphocytic, chronic granulocytic and chronic myelomonocytic leukemias, Hodgkin's and non-Hodgkin's lymphomas, myelofibrosis, and multiple myeloma, but not in patients with chronic lymphocytic leukemia and polycythemia vera, as compared with healthy controls. We followed the serum level of the protein for 18 months. Patients with infectious complications, those receiving cytostatic treatment, and those in the preterminal period had further reduced serum alpha 2-HS glycoprotein levels. The reduction of serum alpha 2-HS glycoprotein concentration was primarily due to decreased production caused by infiltration of the liver, a hepatotoxic effect of cytostatic treatment, and, to a lesser degree, to increased consumption. We found statistically significant negative correlations between serum alpha 2-HS glycoprotein concentration and erythrocyte sedimentation rate, serum aspartate aminotransferase and alkaline phosphatase activities, and IgG and IgM concentrations. The determination of the alpha 2-HS glycoprotein concentration is useful for the assessment and follow-up of the clinical status and therapy of patients with hematological malignancies and also has prognostic significance.
authors.affiliation: 3rd Department of Medicine, Semmelweis University of Medicine, Budapest, Hungary.
authors.forename: L
authors.initials: L
authors.lastname: Kalabay
authors.forename: K
authors.initials: K
authors.lastname: Cseh
authors.forename: S
authors.initials: S
authors.lastname: Benedek
authors.forename: S
authors.initials: S
authors.lastname: Fekete
authors.forename: T
authors.initials: T
authors.lastname: Masszi
authors.forename: K
authors.initials: K
authors.lastname: Herjeczki
authors.forename: T
authors.initials: T
authors.lastname: Pozsonyi
authors.forename: L
authors.initials: L
authors.lastname: Jakab
authors.forename: L
authors.initials: L
authors.lastname: Jakab
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001798:Blood Proteins / Q000032:analysis*; D052776:Female Urogenital Diseases / Q000097:blood / Q000150:complications / Q000382:microbiology; D005500:Follow-Up Studies; D006801:Humans; D007239:Infections / Q000097:blood; D007938:Leukemia / Q000097:blood*; D008099:Liver / Q000473:pathology; D008171:Lung Diseases / Q000097:blood / Q000150:complications / Q000382:microbiology; D008223:Lymphoma / Q000097:blood*; D052801:Male Urogenital Diseases; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood*; D009929:Organ Size; D055728:Primary Myelofibrosis / Q000097:blood*; D013154:Spleen / Q000473:pathology; D060749:alpha-2-HS-Glycoprotein
chemical_list: C556354:AHSG protein, human; D001798:Blood Proteins; D060749:alpha-2-HS-Glycoprotein